Lakefront Biotherapeutics (DE:GXEA)
FRANKFURT:GXEA
GXEA Stock Chart & Stats
€24.40
€1.00(3.68%)
At close: 4:00 PM EST
€24.40
€1.00(3.68%)
Day’s Range― - ―
52-Week Range€22.80 - €31.40
Previous CloseN/A
Volume70.00
Average Volume (3M)22.00
Market Cap
€1.60B
Enterprise Value€1.54B
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.3
Beta0.30
Next Earnings
Aug 10, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.42
Shares Outstanding65,897,070
10 Day Avg. Volume35
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.53Price Target Upside-11.77% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.57
Revenue Forecast (FY)€23.10M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ValuationAnalyst upgrade indicates the company could trade closer to its cash balance as markets reassess a lower-spend profile.
Operating Expense ReductionManagement's decision to wind down the cell therapy unit is expected to remove the majority of the current burn rate and materially cut operating expenses.
Strategic Focus And Business DevelopmentRenewed cost discipline and program prioritization improve the company's readiness to pursue targeted business development or licensing opportunities.
Bears Say
Operational Disruption From Site ClosuresShutting down all non-headquarters sites risks disrupting ongoing research activities and may delay progress on remaining programs.
Restructuring Costs And LiabilitiesLarge-scale layoffs and site closures are likely to generate one-time restructuring expenses and potential severance or legal liabilities.
Workforce Reduction ImpactWind-down of the cell therapy business will impact 365 employees and could create reputational and morale challenges across the organization.
Lakefront Biotherapeutics News
GXEA FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
Lakefront Biotherapeutics lowest stock price was €22.80 and its highest was €31.40 in the past 12 months.
What is Lakefront Biotherapeutics’s market cap?
Lakefront Biotherapeutics’s market cap is €1.60B.
When is Lakefront Biotherapeutics’s upcoming earnings report date?
Lakefront Biotherapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 60 days.
How were Lakefront Biotherapeutics’s earnings last quarter?
Lakefront Biotherapeutics released its earnings results on May 06, 2026. The company reported €0.212 earnings per share for the quarter, beating the consensus estimate of -€0.81 by €1.022.
Is Lakefront Biotherapeutics overvalued?
According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Overvalued.
Does Lakefront Biotherapeutics pay dividends?
Lakefront Biotherapeutics does not currently pay dividends.
What is Lakefront Biotherapeutics’s EPS estimate?
Lakefront Biotherapeutics’s EPS estimate is -0.71.
How many shares outstanding does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Lakefront Biotherapeutics reported an EPS of €0.212 in its last earnings report, beating expectations of -€0.81. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
Currently, no hedge funds are holding shares in DE:GXEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lakefront Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€21.53 (-11.77% Downside)
€21.53 (-11.77% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.37%
12-Months-Change
Fundamentals
Return on Equity
16.88%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Lakefront Biotherapeutics
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
GXEA Company Deck
GXEA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.View all DE:GXEA earnings summariesGXEA Stock 12 Month Forecast
Average Price Target
€21.53
▼(-11.77% Downside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Options Prices
Currently, No data available
---